Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126523701 | 12652370 | 1 | I | 20160808 | 20160815 | 20160815 | EXP | US-TEVA-684150USA | TEVA | WA C, SEMRAD T, SEMRAD AM. COMBINED CHEMOTHERAPY AND RADIATION FOR TREATMENT OF ANAPLASTIC THYROID CANCER (ATC): A CASE REPORT. ENDOCR-REV 2014;:. | 65.00 | YR | M | Y | 0.00000 | 20160815 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126523701 | 12652370 | 1 | PS | CISPLATIN. | CISPLATIN | 1 | Unknown | ADMINISTERED ON DAYS 1 AND 22 | U | 74656 | 60 | MG/M**2 | |||||||
| 126523701 | 12652370 | 2 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | ADMINISTERED WEEKLY FOR 5 WEEKS | U | 75297 | 500 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126523701 | 12652370 | 1 | Anaplastic thyroid cancer |
| 126523701 | 12652370 | 2 | Anaplastic thyroid cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126523701 | 12652370 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126523701 | 12652370 | Dysphagia | |
| 126523701 | 12652370 | Fatigue | |
| 126523701 | 12652370 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |